請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16691
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 潘子明(Tzu-Ming Pan) | |
dc.contributor.author | Cheng-Han Yang | en |
dc.contributor.author | 楊承翰 | zh_TW |
dc.date.accessioned | 2021-06-07T23:43:45Z | - |
dc.date.copyright | 2014-07-29 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-07-16 | |
dc.identifier.citation | 台灣失智症協會官方網站。2014。http://www.tada2002.org.tw/。
李昭蓉。1997。漫談紅麴菌。食品工業月刊。29: 86-89。 邱博恩。2011。芝麻酚與槀本內酯改善老化促進小鼠之學習記憶能力與阿茲海默症病理特徵之潛力。臺灣大學生物資源暨農學院食品科技研究所碩士論文台北。 劉景寬、戴志達、林瑞泰及賴秋蓮。2000。台灣失智症流行病學。應用心理研究。7: 157-169。 動物基因轉殖與疫苗發展技術教學資源中心。2003。動物基因轉殖技術與實驗。台灣。 蘇遠志、陳文亮、方鴻源、翁浩慶與王文祥。1970。紅麴菌 (Monascus anka) 之菌學研究。中國農業化學會誌。8: 45-58。 衛生福利部食品藥物管理署。2009。食品中黴菌毒素檢驗方法-橘黴素之檢驗。台灣。 Alzheimer A. (1907) Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiat Psych-gerichtl Med., 64, 146-148. Akihisa, T., Tokuda, H., Ukiya, M., Kiyota, A., Yasukawa, K., Sakamoto, N., Kimura, Y., Suzuki, T., Takayasu, J., & Nishino, H. (2005). Anti-tumor-initiating effects of monascin, an azaphilonoid pigment from the extract of Monascus pilosus fermented rice (red-mold rice). Chem Biodivers, 2, 1305-1309. Albert, J. S. (2009). Progress in the development of beta-secretase inhibitors for Alzheimer's disease. Prog Med Chem, 48, 133-161. Aniya, Y., Yokomakura, T., Yonamine, M., Shimada, K., Nagamine, T., Shimabukuro, M., & Gibo, H. (1999). Screening of antioxidant action of various molds and protection of Monascus anka against experimentally induced liver injuries of rats. Gen Pharmacol, 32, 225-231. Aucoin, J. S., Jiang, P., Aznavour, N., Tong, X. K., Buttini, M., Descarries, L., & Hamel, E. (2005). Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience, 132, 73-86. Avila, J., Perez, M., Lucas, J. J., Gomez-Ramos, A., Santa Maria, I., Moreno, F., Smith, M., Perry, G., & Hernandez, F. (2004). Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr Alzheimer Res, 1, 97-101. Behl, C., Davis, J. B., Lesley, R., & Schubert, D. (1994). Hydrogen peroxide mediates amyloid beta protein toxicity. Cell, 77, 817-827. Bollen, E. L., Gaw, A., & Buckley, B. M. (2001). Statin therapy and the prevention of dementia. Arch Neurol, 58, 1023-1024. Bowen, D. M., Smith, C. B., White, P., & Davison, A. N. (1976). Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 99, 459-496. Burns, A., & Iliffe, S. (2009). Alzheimer's disease. BMJ, 338, b158. Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., Puolivali, J., Lesne, S., Ashe, K. H., Muchowski, P. J., & Mucke, L. (2007). Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem, 282, 23818-23828. Chu, Y. F., Chang, W. H., Black, R. M., Liu, J. R., Sompol, P., Chen, Y., Wei, H., Zhao, Q., & Cheng, I. H. (2012). Crude caffeine reduces memory impairment and amyloid beta(1-42) levels in an Alzheimer's mouse model. Food Chem, 135, 2095-2102. Crawley, J. N., What's wrong with my mouse? Behavioral phyenotyping of transgenic and knockout mice. (2007). 2nd ed. Wiley-Interscience, New Jersey, U.S.A. d'Abramo, C., Ricciarelli, R., Pronzato, M. A., & Davies, P. (2006). Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem, 98, 1068-1077. Deipolyi, A. R., Fang, S., Palop, J. J., Yu, G. Q., Wang, X., & Mucke, L. (2008). Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging, 29, 253-266. Di Filippo, M., Sarchielli, P., Picconi, B., & Calabresi, P. (2008). Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci, 29, 402-412. Duff, K., & Suleman, F. (2004). Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic, 3, 47-59. Endo, A. (1979). Monacolin-K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot. 32, 852-854. Escribano, L., Simon, A. M., Gimeno, E., Cuadrado-Tejedor, M., Lopez de Maturana, R., Garcia-Osta, A., Ricobaraza, A., Perez-Mediavilla, A., Del Rio, J., & Frechilla, D. (2010). Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology, 35, 1593-1604. Forstl, H., & Kurz, A. (1999). Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci, 249, 288-290. Furukawa, K., Barger, S. W., Blalock, E. M., & Mattson, M. P. (1996). Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature, 379, 74-78. Furuta, A., Price, D. L., Pardo, C. A., Troncoso, J. C., Xu, Z. S., Taniguchi, N., & Martin, L. J. (1995). Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol, 146, 357-367. Gakhar-Koppole, N., Hundeshagen, P., Mandl, C., Weyer, S. W., Allinquant, B., Muller, U., & Ciccolini, F. (2008). Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur J Neurosci, 28, 871-882. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Wolozin, B., &Zhao J. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature, 373, 523-527. Gomolin, I. H., Smith, C., & Jeitner, T. M. (2010). Once-daily memantine: pharmacokinetic and clinical considerations. J Am Geriatr Soc, 58, 1812-1813. Hsiao, K. Chapman, P. Nilsen, S. Eckman, C. Harigaya, Y. Younkin, S. (1996) Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science. 274, 99-102. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353-356. Hsu, W. H., Chen, T. H., Lee, B. H., Hsu, Y. W., & Pan, T. M. (2014). Monascin and ankaflavin act as natural AMPK activators with PPARalpha agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. Food Chem Toxicol, 64, 94-103. Hsu, W. H., Lee, B. H., Liao, T. H., Hsu, Y. W., & Pan, T. M. (2012). Monascus-fermented metabolite monascin suppresses inflammation via PPAR-gamma regulation and JNK inactivation in THP-1 monocytes. Food Chem Toxicol, 50, 1178-1186. Jarrett, J. T., Berger, E. P., & Lansbury, P. T., Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry, 32, 4693-4697. Jelicic, M., Bonebakker, A. E., & Bonke, B. (1995). Implicit memory performance of patients with Alzheimer's disease: a brief review. Int Psychogeriatr, 7, 385-392. Keller, J. N., Mark, R. J., Bruce, A. J., Blanc, E., Rothstein, J. D., Uchida, K., Waeg, G., & Mattson, M. P. (1997). 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience, 80, 685-696. Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008). PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics, 5, 481-489. Lee, B. H., Hsu, W. H., Huang, T., Chang, Y. Y., Hsu, Y. W., & Pan, T. M. (2013). Monascin improves diabetes and dyslipidemia by regulating PPARgamma and inhibiting lipogenesis in fructose-rich diet-induced C57BL/6 mice. Food Funct, 4, 950-959. Lee, C. L., Wang, J. J., Kuo, S. L., & Pan, T. M. (2006). Monascus fermentation of dioscorea for increasing the production of cholesterol-lowering agent--monacolin K and antiinflammation agent--monascin. Appl Microbiol Biotechnol, 72, 1254-1262. Lee, C. L., Wang, J. J., & Pan, T. M. (2008). Red mold rice extract represses amyloid beta peptide-induced neurotoxicity via potent synergism of anti-inflammatory and antioxidative effect. Appl Microbiol Biotechnol, 79, 829-841. Lee C. L., Kuo T. F., Wang J. J., Pan T. M. (2007). Red mold rice ameliorates impairment of memory and learning ability in intracerebroventricular amyloid beta-infused rat by repressing amyloid beta accumulation. J Neurosci Res. 85, 3171-3182. Liu, B., & Hong, J. S. (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther, 304, 1-7. Maier, C. M., & Chan, P. H. (2002). Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist, 8, 323-334. Mattson, M. P. (1997). Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev, 77, 1081-1132. Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature, 430, 631-639. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., & Rydel, R. E. (1993). Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron, 10, 243-254. Michaelis, M. L., Dobrowsky, R. T., & Li, G. (2002). Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci, 19, 289-293. Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., & Iqbal, K. (1993). Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys, 301, 41-52. Miller, J. L. (1999). Rosiglitazone approved for treatment of type 2 diabetes. Am J Health Syst Pharm, 56, 1292-1294. Morawietz, G., Ruehl-Fehlert, C., Kittel, B., Bube, A., Keane, K., Halm, S., Heuser, A., Hellmann, J., Group, R., & Group, N. (2004). Revised guides for organ sampling and trimming in rats and mice--Part 3. A joint publication of the RITA and NACAD groups. Exp Toxicol Pathol, 55, 433-449. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000). High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci, 20, 4050-4058. Nordberg, A. (2008). Amyloid imaging in Alzheimer's disease. Neuropsychologia, 46, 1636-1641. Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003). Alzheimer's disease: the cholesterol connection. Nat Neurosci, 6, 345-351. Querfurth, H. W., LaFerla, F. M. (2010). Alzheimer's disease. N Engl J Med, 362, 329-344. Ratner, M. (2005). FDA pharmacogenomics guidance sends clear message to industry. Nat Rev Drug Discov, 4, 359. Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013). Statins and cognitive function: a systematic review. Ann Intern Med, 159, 688-697. Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., Walter, J., Klockgether, T., van Leuven, F., & Heneka, M. T. (2006). Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A, 103, 443-448. Scarpini, E., Scheltens, P., & Feldman, H. (2003). Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol, 2, 539-547. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., & Seubert, P. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177. Schenk, D., Hagen, M., & Seubert, P. (2004). Current progress in beta-amyloid immunotherapy. Curr Opin Immunol, 16, 599-606. Selkoe, D. J. (1997). Alzheimer's disease: genotypes, phenotypes, and treatments. Science, 275, 630-631. Sheng, J. G., Zhu, S. G., Jones, R. A., Griffin, W. S., Mrak, R. E. (2000). Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol. 163, 388-391. Shi, Y. C., & Pan, T. M. (2011). Beneficial effects of Monascus purpureus NTU 568-fermented products: a review. Appl Microbiol Biotechnol, 90, 1207-1217. Siemers E, Skinner M, Dean R.A., Gonzales C, Satterwhite J, Farlow M, Ness D, May P. C. (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 28, 126-132. Simard, A. R., Soulet, D., Gowing G., Julien, J. P., Rivest, S. (2006). Bonemarrow-derived microglia play a critical role in restricting senileplaque formation in Alzheimer’s disease. Neuron 49, 489–502. Taira, J., Miyagi, C., & Aniya, Y. (2002). Dimerumic acid as an antioxidant from the mold, Monascus anka: the inhibition mechanisms against lipid peroxidation and hemeprotein-mediated oxidation. Biochem Pharmacol, 63, 1019-1026. Tong, X. K., Nicolakakis, N., Fernandes, P., Ongali, B., Brouillette, J., Quirion, R. Hamel, E.(2009). Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiology of Disease, 35, 406-414. Wu, C. L., Lee, C. L & Pan, T. M. (2009). Red mold dioscorea has a greater antihypertensive effect than traditional red mold rice in spontaneously hypertensive rats. J Agric Food Chem, 57, 5035-5041. Yoshiike, Y., Chui, D. H., Akagi, T., Tanaka, N., & Takashima, A. (2003). Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. J Biol Chem, 278, 23648-23655. Zahs, K. R., & Ashe, K. H. (2010). 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci, 33, 381-389. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16691 | - |
dc.description.abstract | In the recent research, it has been discovered that red mold rice has the potential to ameliorate the symptom of Alzheimer’s disease (AD), by the functional factor such as monacolin K, γ-aminobutyric acid (GABA), dimerumic acid, ankaflavin and monascin. Using dioscorea as substrate for Monascus purpureus fermentation, it can produce higher amount of functional ingredients, ankaflvin and monascin. In this study, we investigate the effect of red mold dioscorea (RMD) to ameliorate Alzheimer’s disease pathophysiology. Using 4 month-old Alzheimer’s disease transgenic mice J20 feeding with RMD for two months, we found that J20 mice fed with RMD have better learning and memory ability then the control group in behavior test such as passive avoidance and Morris water maze. Analyzing the symptoms related to AD, we found that in the brain of J20 mice fed with RMD, there’s a significant decrease in the amount of Aβ1-40, 1-42 and enzyme activity of acetylcholinesterase. After confirming the effect of RMD in AD, we use positive control, rosiglitazone group as reference to investigate the mechanism of RMD to ameliorate AD. In decreasing p-tau level, activating the CD36 marker gene expression which related to microglia clearing Aβ, decreasing gene expression of γ-secretase, we found that RMD has the same effect as rosiglitazone, a PPARγ agonist. According to the previous research that pigments in RMD, monascin and ankaflavin, have the characteristic of PPARγ agonist combined with our results, we assumed that one of the mechanism of RMD to ameliorate AD may through monascin and ankaflavin, as PPAR γagonist rosiglitazone, activate PPARγ to effect it. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T23:43:45Z (GMT). No. of bitstreams: 1 ntu-103-R01b22029-1.pdf: 4641366 bytes, checksum: e3f1938555b59880726443c4a26e730f (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 目 錄
謝誌..........................................................I 縮寫表........................................................II 中文摘要......................................................IV 英文摘要.......................................................V 目錄..........................................................VI 表目錄......................................................VIII 圖目錄.........................................................IX 第壹章 文獻回顧..................................................1 ㄧ、阿茲海默症之文獻回顧...........................................1 (一) 阿茲海默症與失智症..........................................1 (二) 阿茲海默症形成機制..........................................2 (三) 阿茲海默症之治療藥物.........................................6 二、PPAR γ促效劑與阿茲海默症......................................10 (一) 調控類澱粉蛋白代謝..........................................11 (二) 調控能量代謝...............................................11 (三) 降低發炎反應...............................................13 (四) 調節血脂...................................................13 三、實驗餵食樣品..................................................14 (ㄧ) 紅麴山藥...................................................14 (二) 梵蒂亞.....................................................18 四、阿茲海默症基因轉殖鼠............................................19 第貳章 研究動機與目的..............................................23 第參章 材料與方法..................................................25 ㄧ、實驗材料......................................................25 二、實驗方法......................................................27 第肆章 結果與討論..................................................38 ㄧ、基因轉殖鼠基因型態鑑定...........................................38 二、餵食紅麴山藥、rosiglitazone八周後對J20小鼠記憶學習能力之影響.........38 三、餵食紅麴山藥、rosiglitazone八周後對J20小鼠體重之影響...............45 四、安全性試驗分析.................................................45 五、餵食紅麴山藥、rosiglitazone八周後對J20小鼠腦中類澱粉蛋白之影響.......48 六、餵食紅麴山藥、rosiglitazone八周後對J20小鼠腦中乙醯膽鹼酯酶活性之影響..54 七、餵食紅麴山藥、rosiglitazone八周後對J20小鼠腦中基因表現量之影響.57 八、餵食紅麴山藥、rosiglitazone八周後對J20小鼠腦中P-tau蛋白之影響.60 九、餵食紅麴山藥、rosiglitazone八周後對J20小鼠腦中的抗氧化能力之影響60 十、餵食紅麴山藥、rosiglitazone八周後對J20小鼠腦中細胞激素TNF-α 之影響69 第伍章 結論.......................................................74 第陸章 參考文獻....................................................76 | |
dc.language.iso | zh-TW | |
dc.title | 利用基因轉殖鼠 J20 模式探討 Monascus purpureus NTU 568
發酵產物對阿茲海默症病徵延緩及改善記憶學習能力之研究 | zh_TW |
dc.title | The study of fermented product of Monascus purpureus NTU 568 to ameliorate learning/memory impairment and Alzheimer’s disease pathophysiology in J20 Alzheimer’s disease transgenic mice | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李俊霖(Chun-Lin Lee),蕭勝煌(Sheng-Huang Hsiao),陳人豪(Jen-Hau Chen),林志輝(Chih-Hui Lin) | |
dc.subject.keyword | 阿茲海默症,基因轉殖鼠J20,紅麴山藥,rosiglitazone,monascin,ankaflavin,PPARγ 促效劑。, | zh_TW |
dc.subject.keyword | Alzheimer’s disease,transgenic mice J20,red mold dioscorea,rosiglitazone,monascin,ankaflavin,PPARγ agonist., | en |
dc.relation.page | 84 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2014-07-16 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 4.53 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。